Tenofovir alafenamide is generally well tolerated and was designed to reduce the two long-standing concerns with the older tenofovir. It has its own profile, which is metabolic rather than organ-related.
What happens in the first weeks?
Nausea, headache, tiredness and loose stools occur in a minority and usually settle within two to four weeks. Taking the tablet with food helps, and most combinations containing it should be taken with food anyway.
How does it compare on kidney effects?
Better. Markers of kidney function and of tubular damage are consistently more favourable than with the older form, and people switching over generally see improvement. Kidney monitoring still happens, because the risk is reduced rather than removed.
How does it compare on bones?
Also better. Bone mineral density declines less, and switching from the older form is associated with partial recovery. This makes it the preferred option for anyone with osteoporosis or a history of fragility fractures.
What about weight gain?
The effect that has attracted most attention. Weight gain is more commonly reported on alafenamide than on the older form, particularly in combination with integrase inhibitors, and this regimen pairing is common. Some of it reflects a return to health after starting treatment and some appears to be a drug effect.
Is that a reason not to take it?
Not by itself. The weight change is modest on average and varies considerably between individuals. It is worth monitoring and worth raising if it is troubling you, because alternatives exist and the older tenofovir has the opposite tendency.
What about cholesterol?
Total cholesterol, LDL and triglycerides tend to be higher than on the older tenofovir. Part of that is because the older drug has a mild lipid-lowering effect rather than because alafenamide raises lipids actively. Whether it matters for cardiovascular risk over decades is not settled and lipids are monitored routinely.
Who should think carefully about this?
Anyone with existing cardiovascular risk factors: high cholesterol, high blood pressure, diabetes, a family history of early heart disease, or a history of smoking. For those people the trade-off between kidney protection and lipid effects is a genuine discussion to have.
What about hepatitis B?
Not a side effect of taking it but of stopping. Alafenamide suppresses hepatitis B, so abrupt withdrawal in someone with chronic infection can cause a serious liver flare. Hepatitis B status is checked before starting and stopping must be planned.
Are there rare serious reactions?
Lactic acidosis with liver enlargement has been reported with this class, though it is uncommon with the newer agents. Severe abdominal pain, marked breathlessness, unusual weakness or persistent vomiting warrant prompt attention rather than waiting.
What monitoring picks these up?
Blood tests every three to six months covering viral load, kidney and liver function and a lipid profile, with weight recorded at appointments. Most changes appear on a blood test long before anyone notices a symptom.
When should you contact your clinic?
Side effects lasting beyond a month, rapid or substantial weight change, or anything making you consider stopping. Switching between tenofovir forms, or to a regimen containing neither, is straightforward and is a conversation worth having rather than a last resort.
Do side effects indicate anything about effectiveness?
No. How you feel bears no relationship to how well the virus is being suppressed. Blood tests are the only reliable indicator, which is why they continue even when everything feels fine.
How do you tell which component is responsible?
Frequently you cannot without changing something. Combination tablets contain three or four drugs and side effects are rarely attributable by symptom alone. A clinician can usually narrow it by pattern and timing, and switching one component is often possible.
Should you look side effects up online?
The patient information leaflet lists everything ever reported, including things that occurred once in a trial, which makes it alarming and not very useful for judging likelihood. A clinic pharmacist will tell you which effects are actually common, which are rare and which matter, in about two minutes.